Imaging agent developer ImaginAb and GlaxoSmithKline unit GSK Clinical Imaging Centre (CIC) have inked two research collaboration agreements.
ImaginAb and GSK CIC will re-engineer a clinical therapeutic antibody currently being developed by GSK into recombinant antibody fragments for diagnostic imaging, according to ImaginAb of Inglewood, CA. Based at Hammersmith Hospital in London, GSK CIC is a collaboration between GlaxoSmithKline, Imperial College London, and the Medical Research Centre (MRC).
GSK CIC's collaboration with ImaginAb is part of the firm's continued exploration of the role of biologics in diagnostic imaging with PET, according to GSK CIC head Dr. Paul Matthews.
Related Reading
ImaginAb licenses BZL technology, October 13, 2009
Aposense teams with GlaxoSmithKline, June 8, 2009
FDA warns Glaxo on cancer drug promotions, November 28, 2007
Copyright © 2010 AuntMinnie.com
